Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Pharm Belg ; 47(4): 323-7, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1357130

RESUMEN

Nebivolol is a mixture of equal amounts of two enantiomers: SR3-nebivolol (d-nebivolol) and RS3-nebivolol (l-nebivolol). SR3-nebivolol is a potent and selective beta 1-adrenergic antagonist both in vitro and in vivo. Nebivolol acutely lowers blood pressure in spontaneously hypertensive rats and induces a slight decrease in total peripheral vascular resistance and a slight increase in cardiac output in anaesthetised dogs. These hemodynamics effects cannot be explained by beta 1-adrenergic antagonism and are largely attributable to RS3-nebivolol.


Asunto(s)
Antagonistas Adrenérgicos beta/farmacología , Benzopiranos/farmacología , Etanolaminas/farmacología , Hemodinámica/efectos de los fármacos , Animales , Antihipertensivos/farmacología , Presión Sanguínea/efectos de los fármacos , Gasto Cardíaco/efectos de los fármacos , Perros , Nebivolol , Ratas , Ratas Endogámicas SHR , Receptores Adrenérgicos beta/efectos de los fármacos , Resistencia Vascular/efectos de los fármacos
2.
J Cardiovasc Pharmacol ; 20(5): 705-14, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1280731

RESUMEN

The cardiac in vitro effects of R 80122, a novel phosphodiesterase (PDE) inhibitor, were investigated and compared with those of the reference compound milrinone and of the calcium-sensitizer adibendan. In guinea pig left atria, both milrinone and R 80122 increased contractile force; 10 microM milrinone was equieffective to 1 microM R 80122. The rate of spontaneously beating atria was not altered by R 80122 in the concentration range of 0.01-0.3 microM. Higher concentrations (1-10 microM) led to a statistically insignificant increase of 20%. Milrinone's effect on frequency was more pronounced and amounted to 21% at 10 microM and to 40% at 100 microM. Adibendan increased heart rate (HR) by 10% at a concentration of only 0.03 microM. This effect was not enhanced any further by increasing the concentration. In papillary muscle, the positive inotropic effects of both milrinone and R 80122 were inhibited by carbachol, indicating involvement of cyclic AMP. Further indications for a cyclic AMP-dependent action were obtained by induction of slow action potentials and synergism with isoprenaline. In electrophysiologic measurements, milrinone reduced action potential duration (APD) in a high concentration whereas R 80122 had no effect. Action potential changes elicited by a toxic concentration of ouabain were reduced by R 80122. Relaxation of rat aortic rings contracted by KCl and relaxation of guinea pig aortic rings contracted by norepinephrine (NE) was comparable for both milrinone and R 80122. R 80122 also caused relaxation of canine coronary arteries constricted with prostaglandin F2 alpha (PGF2 alpha) both with and without endothelium. NE-induced contractions in canine gastrosplenic arteries were not affected by R 80122. Cardiac contractility that had been impaired to various degrees by pentobarbital or by aging was restored to control values by both milrinone and R 80122. R 80122 enhanced cardiac contractility at lower concentrations than milrinone with no concomitant increase in frequency or shortening of the action potential, which may be advantageous for treatment of heart failure.


Asunto(s)
Bencimidazoles , Frecuencia Cardíaca/efectos de los fármacos , Imidazoles/farmacología , Contracción Miocárdica/efectos de los fármacos , Músculos Papilares/efectos de los fármacos , Inhibidores de Fosfodiesterasa/farmacología , Quinazolinas/farmacología , Potenciales de Acción/efectos de los fármacos , Animales , Carbacol/farmacología , Femenino , Cobayas , Técnicas In Vitro , Isoproterenol/farmacología , Masculino , Milrinona , Norepinefrina/farmacología , Ouabaína/farmacología , Oxindoles , Músculos Papilares/fisiología , Piridonas/farmacología , Estimulación Química , Vasodilatadores/farmacología
3.
J Cardiovasc Pharmacol ; 17(6): 964-9, 1991 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-1714022

RESUMEN

Nebivolol is a new beta 1-antagonist that acutely reduces arterial blood pressure without depressing cardiac function. The present study was designed to determine the effect of nebivolol on coronary arteries. Rings of canine left anterior descending coronary (LAD) artery with or without endothelium were suspended in organ chambers and the isometric tension was recorded. In some experiments, the transmembrane potential of the smooth muscle cells was recorded by electrophysiological methods. During contractions to prostaglandin F2 alpha, nebivolol induced concentration-dependent relaxations of the coronary arteries. The enantiomer, l-nebivolol, also induced comparable relaxations; however, d-nebivolol induced smaller relaxations. The relaxations induced by nebivolol and its enantiomer were significantly larger in tissues with than in those without endothelium. The differences between tissues with and without endothelium were abolished by nitro-L-arginine (3 x 10(-5) M) or methylene blue (10(-5) M). The nebivolol-induced relaxations were not affected by indomethacin (10(-5) M), phentolamine (5 x 10(-6) M), propranolol (5 x 10(-6) M), or methysergide (3 x 10(-6) M). Nebivolol at a subthreshold concentration for inducing relaxation (3 x 10(-7) M) did not significantly affect endothelium-dependent relaxations to acetylcholine but potentiated ADP-induced endothelium-dependent relaxations. The potentiation is stereoselective for l-nebivolol. Nebivolol induced a small hyperpolarization of the coronary smooth muscle with endothelium (1 mV).(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Antagonistas Adrenérgicos beta/farmacología , Benzopiranos/farmacología , Vasos Coronarios/efectos de los fármacos , Endotelio Vascular/efectos de los fármacos , Etanolaminas/farmacología , Relajación Muscular/efectos de los fármacos , Animales , Vasos Coronarios/fisiología , Dinoprost/farmacología , Perros , Electrofisiología , Endotelio Vascular/fisiología , Femenino , Masculino , Potenciales de la Membrana/efectos de los fármacos , Contracción Muscular/efectos de los fármacos , Relajación Muscular/fisiología , Músculo Liso Vascular/citología , Músculo Liso Vascular/efectos de los fármacos , Músculo Liso Vascular/fisiología , Nebivolol
4.
Thromb Haemost ; 64(1): 91-6, 1990 Aug 13.
Artículo en Inglés | MEDLINE | ID: mdl-2148850

RESUMEN

Ridogrel (6.3 x 10(-6) to 10(-4) M) inhibited contractions of isolated rat caudal arteries and rabbit femoral arteries caused by U-46619. The slope of an Arunlakshana-Schild plot (pA2-value: 3.4 x 10(-6) M) on the caudal artery was slightly higher than one (1.14). This effect was maximal within 20 min of incubation of the blood vessel with the compound and easily reversible. Ridogrel antagonised contractions of isolated rabbit femoral arteries caused by prostaglandin F2 alpha in the same concentration range. Ridogrel also inhibited contractions induced by aggregating rat platelets on isolated rat caudal arteries (in the presence of ketanserin 4 x 10(-7) M) and on isolated rabbit pulmonary and femoral arteries (in the absence of ketanserin). Ridogrel had no effect on Ca2(+)-induced contractions in depolarised isolated rabbit femoral arteries, and at 10(-4) M antagonised serotonin-induced contractions in this blood vessel. Its effect on serotonin-induced contractions was statistically significant but very small on isolated rat caudal arteries. These observations indicate that ridogrel is an antagonist of prostaglandin endoperoxide/thromboxane A2 and prostaglandin F2 alpha receptors on vascular smooth muscle.


Asunto(s)
Ácidos Pentanoicos/farmacología , Activación Plaquetaria/fisiología , Endoperóxidos de Prostaglandinas Sintéticos/farmacología , Piridinas/farmacología , Tromboxano-A Sintasa/antagonistas & inhibidores , Vasoconstricción/efectos de los fármacos , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico , Animales , Arterias/efectos de los fármacos , Técnicas In Vitro , Activación Plaquetaria/efectos de los fármacos , Conejos , Ratas , Receptores de Prostaglandina/antagonistas & inhibidores , Receptores de Tromboxanos , Antagonistas de la Serotonina/farmacología , Tromboxanos
5.
Eur J Pharmacol ; 159(1): 89-95, 1989 Jan 02.
Artículo en Inglés | MEDLINE | ID: mdl-2565239

RESUMEN

Nebivolol is a chemically novel, potent and selective beta 1-adrenoceptor-blocking agent that acutely lowers arterial blood pressure in hypertensive patients and rats without depressing, or even enhancing, left ventricular function. These properties could be compatible with a partial agonistic effect of beta-adrenoceptor-blocking agents. It was the aim of the present study to investigate whether nebivolol has intrinsic sympathomimetic properties. The study was performed on reserpinized dogs and spontaneously hypertensive rats, and on various isolated tissues from various species. Unlike pindolol and practolol, nebivolol did not exert a stimulating effect on the heart rate and left ventricular function in reserpinized animals and/or in isolated atria of reserpinized rats at doses that are clinically active. Nebivolol did not induce relaxation of isolated coronary arteries and saphenous veins at concentrations that block beta-adrenoceptors. These findings indicate that nebivolol is devoid of intrinsic sympathomimetic activity at clinically relevant doses.


Asunto(s)
Antagonistas Adrenérgicos beta/farmacología , Benzopiranos/farmacología , Etanolaminas/farmacología , Hemodinámica/efectos de los fármacos , Simpatomiméticos , Animales , Presión Sanguínea/efectos de los fármacos , Perros , Electrocardiografía , Femenino , Cobayas , Frecuencia Cardíaca/efectos de los fármacos , Técnicas In Vitro , Contracción Isométrica/efectos de los fármacos , Masculino , Músculo Liso Vascular/efectos de los fármacos , Nebivolol , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas , Reserpina/farmacología
6.
Acta Otolaryngol Suppl ; 460: 42-9, 1988.
Artículo en Inglés | MEDLINE | ID: mdl-3074619

RESUMEN

Flunarizine is a selective Ca++-antagonist with weaker H1-histaminergic antagonistic properties. Flunarizine reduces vasospasm caused by an exaggerated Ca++-influx in depolarized arteries and by vasoactive substances released from aggregating platelets. This Ca++-antagonist also antagonizes the mutual amplification of the vasoconstrictor action of the platelet products. Flunarizine is particularly effective in the cerebral blood vessels, also when they are hyperreactive because of hypoxia. The compound does not interfere with normal arteriolar autoregulation or heart function. Thus flunarizine may be particularly effective in preventing vasospasm without lowering blood pressure or inducing a steal phenomenon.


Asunto(s)
Venas Cerebrales/efectos de los fármacos , Flunarizina/farmacología , Vasoconstricción/efectos de los fármacos , Animales , Venas Cerebrales/fisiología , Humanos
7.
Ann N Y Acad Sci ; 522: 234-47, 1988.
Artículo en Inglés | MEDLINE | ID: mdl-2837122

RESUMEN

Vasoconstriction results from an exaggerated increase of intracellular Ca2+ concentration which initiates the contractile process within the vascular smooth muscle. The dependency of these cells on extracellular Ca2+ to trigger the contractile process when exposed to naturally occurring vasoactive substances such as those released from aggregating blood platelets varies in different vascular areas. This is one of the factors that determine the different sensitivity to the inhibitory effect of various calcium antagonist. A blood vessel can be more reactive to some calcium antagonists than to others, depending on the vascular area. Experiments on isolated cerebral arteries suggest that inhibition of cerebral vasoconstriction is observed with substances such as flunarizine under conditions of vascular hyperresponsiveness generated by acute or chronic pathological conditions or triggered by interaction between vasoactive substances. In this regard marked differences exist between the individual calcium antagonists. Those that are selective for slow Ca2+ channels will inhibit myocardial contractile force and decrease vascular myogenic activity (e.g., at the arteriolar level). Such inhibitory activity is not observed with flunarizine, which affects Ca2+ entry rather selectively, when calcium overload is imposed upon the vasculature, in particular at cerebrovascular sites. This suggests a potential use of this compound in a number of neurological disorders related to cerebral ischemia.


Asunto(s)
Bloqueadores de los Canales de Calcio/farmacología , Músculo Liso Vascular/efectos de los fármacos , Vasoconstrictores/farmacología , Animales , Receptores Adrenérgicos alfa/fisiología , Vasoconstricción/efectos de los fármacos
8.
J Cardiovasc Pharmacol ; 11 Suppl 1: S10-5, 1988.
Artículo en Inglés | MEDLINE | ID: mdl-2459506

RESUMEN

Serotonin enhances (amplifies) the vasoconstrictor effect of norepinephrine not only on isolated large blood vessels and isolated perfused vascular beds but also in vivo. This amplification can be observed with endogenous serotonin released from aggregating platelets and with endogenous norepinephrine released from the adrenergic nerves in the blood vessel wall. It is due to an interaction between S2-serotonergic and alpha 1-adrenergic mechanisms. Combined S2-serotonergic and alpha 1-adrenergic antagonism is more effective than either one alone against contractions evoked with the combination of serotonin and an alpha 1-adrenergic agonist. In spontaneously hypertensive rats, S2-serotonergic antagonism alone does not reduce blood pressure but combined S2-serotonergic and alpha 1-adrenergic blockade lowers blood pressure more than alpha 1-adrenergic blockade alone. This suggests that the interaction between S2-serotonergic and alpha 1-adrenergic vasoconstrictor responses may play a role in the maintenance of high blood pressure.


Asunto(s)
Músculo Liso Vascular/fisiología , Receptores Adrenérgicos alfa/fisiología , Receptores de Serotonina/fisiología , Animales , Contracción Muscular , Norepinefrina/farmacología , Norepinefrina/fisiología , Serotonina/farmacología , Serotonina/fisiología , Vasoconstricción/efectos de los fármacos
9.
Naunyn Schmiedebergs Arch Pharmacol ; 334(4): 327-32, 1986 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-3821925

RESUMEN

Isolated kidneys of Wistar rats and spontaneously hypertensive rats (SHR) were perfused with Tyrode's solution. In 2- and 6-month old SHR, the maximal increase in perfusion pressure caused by norepinephrine was higher than in 2- and 6-month old Wistar rats, but the sensitivity, as judged from the dose of the agonist required to reach 50% of the maximal response was the same. Both the maximal response and the sensitivity to serotonin were significantly augmented in 6-month old SHR and Wistar rats when compared to the young animals. This hypersensitivity was more pronounced in SHR than in Wistar rats. Infusion of serotonin potentiated the vasoconstriction induced by a bolus of norepinephrine. This amplification, due to activation of S2-serotonergic receptors, was more pronounced in the old animals. No amplification occurred when norepinephrine was infused instead of serotonin. Tachyphylaxis to the amplifying effect of serotonin was observed and was less pronounced in kidneys from old than from young animals. The amplifying effect of serotonin was inhibited by ketanserin at concentrations which did not, or only moderately, inhibit the response to norepinephrine.


Asunto(s)
Hipertensión/fisiopatología , Circulación Renal/efectos de los fármacos , Serotonina/farmacología , Envejecimiento , Animales , Presión Sanguínea/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Técnicas In Vitro , Masculino , Norepinefrina/farmacología , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas , Taquifilaxis
10.
J Hypertens Suppl ; 4(1): S55-9, 1986 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-2939213

RESUMEN

Serotonin induces constrictor responses on smooth muscle tissues from several vascular regions mainly by its interaction with serotonin-S2 receptor sites. The individual sensitivity of various blood vessels to serotonin may vary considerably. Serotonin (e.g. released from aggregating platelets) also induces vascular contractions by amplifying the response to other vasoactive substances. The vascular reactivity to serotonin can be markedly augmented by acute hypoxia (95% N2, 5% CO2; canine coronary arteries) and by cooling from 37 degrees to 29 degrees C (rabbit tibial and canine saphenous arteries). Blood vessels become hyperreactive to the vasoconstrictor component of serotonin in a number of disease states. Isolated perfused kidneys from spontaneously hypertensive rats (SHR) exhibit direct and indirect (amplifying) vasoconstrictor responses to serotonin. The amplifying effect of serotonin is significantly more pronounced in 6-month-old than in 2-month-old SHRs. Both the direct and indirect vasoconstrictor responses to serotonin, whether or not augmented by acute or chronic conditions, are inhibited by the serotonin-S2 receptor antagonist, ketanserin (4 X 10(-10) to 4 X 10(-7) mol/l). Both the hypersensitivity of vascular tissue to serotonin and the amplifying effect of the amine may greatly contribute to hypertension and other cardiovascular disorders.


Asunto(s)
Piperidinas/farmacología , Antagonistas de la Serotonina , Serotonina/farmacología , Vasoconstricción/efectos de los fármacos , Animales , Sinergismo Farmacológico , Ketanserina , Norepinefrina/metabolismo , Conejos , Ratas , Ratas Endogámicas , Ovinos , Vasodilatación/efectos de los fármacos
11.
Pharmacol Res Commun ; 17(7): 585-608, 1985 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-2931729

RESUMEN

Serotonin causes contraction of the vascular smooth muscle cells in most blood vessels studied in vitro. This contraction is mainly due to activation of S2-serotonergic receptors. The monoamine can cause relaxation through activation of serotonergic receptors, different from the S2-serotonergic receptor and located on endothelial cells, or through an inhibitory effect on adrenergic neurotransmission. In certain blood vessels, the contractile effects can be markedly enhanced by hypoxia or moderate cooling. At low concentrations serotonin amplifies the vasoconstrictor responses to other vasoactive substances. Ultimately the effect of serotonin on vascular constriction is defined by the balance between these different actions. In the intact organism under normal conditions serotonin may play a modulatory role but exacerbation of the contractile effects because of hypersensitivity of the smooth muscle cells, local physical or humoral factors or loss of the relaxatory ability may lead to abnormal tissue responses. Thus, serotonin-induced vasoconstrictor responses may play a role in the etiology of vasospasm and peripheral vascular diseases, in particular at sites of endothelial lesions. Both the vasoconstrictor and the platelet aggregating effects of serotonin combined with its accelerated turnover may be important in the induction and maintenance of the augmented peripheral vascular resistance in arterial hypertension.


Asunto(s)
Modelos Biológicos , Serotonina/fisiología , Vasoconstricción , Vasodilatación , Animales , Plaquetas/metabolismo , Calcio/metabolismo , Frío , Estimulación Eléctrica , Hipoxia/fisiopatología , Ketanserina , Lidoflazina/farmacología , Metiotepina/farmacología , Metisergida/farmacología , Microcirculación , Contracción Muscular/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Piperidinas/farmacología , Receptores de Serotonina/metabolismo , Flujo Sanguíneo Regional , Antagonistas de la Serotonina/farmacología
12.
Arch Int Pharmacodyn Ther ; 276(1): 28-34, 1985 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-3840350

RESUMEN

Experiments were performed to evaluate the effects of BM 13.177 on vascular smooth muscle. Rabbit femoral arteries were mounted for isometric tension recording and made to contract with the endoperoxide analogues U44064 and U46619, prostaglandin F2 alpha and E2, norepinephrine, serotonin, histamine and ATP in the absence and in the presence of BM 13.177. This compound (7 X 10(-5)M) inhibited contractions to the endoperoxide analogues and did not affect or slightly potentiated contractions induced with the other agonists except for those evoked with prostaglandin F2 alpha, which tended to be slightly inhibited. In 2 out of 5 unstimulated preparations tested, BM 13.177 at 7 X 10(-6) and 7 X 10(-5)M caused small contractions. It is suggested that BM 13.177 is a selective thromboxane A2 receptor antagonist in vascular smooth muscle.


Asunto(s)
Fibrinolíticos/farmacología , Músculo Liso Vascular/efectos de los fármacos , Endoperóxidos de Prostaglandinas Sintéticos/farmacología , Sulfonamidas/farmacología , Animales , Técnicas In Vitro , Contracción Muscular/efectos de los fármacos , Endoperóxidos de Prostaglandinas Sintéticos/antagonistas & inhibidores , Conejos
15.
Blood Vessels ; 19(3): 126-34, 1982.
Artículo en Inglés | MEDLINE | ID: mdl-7074226

RESUMEN

The aim of the present study was to assess whether or not thrombin affects vascular smooth muscle activity by a direct action on the blood vessel wall. In isolated saphenous veins and femoral and pulmonary arteries thrombin did not affect basal tension, but in pulmonary and portal mesenteric veins it caused contraction. In saphenous and femoral veins and in femoral and pulmonary arteries the enzyme depressed contractions evoked by alpha-adrenergic stimulation. In the saphenous vein thrombin also depressed contractions induced with acetylcholine or potassium ions. In this blood vessel the relaxation caused by thrombin was abolished by antithrombin III and the tripeptide D-phenylalanine-proline-arginine-CH2Cl, a specific inhibitor of the enzyme center of thrombin. In pulmonary and portal mesenteric veins, thrombin potentiated the contractile response to norepinephrine. These contractile effects of thrombin were also abolished by D-phenylalanine-proline-arginine-CH2Cl. Thus, thrombin causes relaxation or contraction of blood vessels through a direct action on the blood vessel wall. These effects are due to its proteolytic activity.


Asunto(s)
Contracción Muscular/efectos de los fármacos , Relajación Muscular/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Trombina/farmacología , Acetilcolina/farmacología , Animales , Bovinos , Perros , Humanos , Norepinefrina/farmacología , Fentolamina/farmacología , Propranolol/farmacología , Arteria Pulmonar/efectos de los fármacos , Vena Safena/efectos de los fármacos
16.
Eur J Pharmacol ; 72(2-3): 189-98, 1981 Jun 19.
Artículo en Inglés | MEDLINE | ID: mdl-6265245

RESUMEN

In canine blood vessels acetylcholine and adenosine inhibit the exocytotic release of norepinephrine during nerve stimulation. The present experiments were designed to determine the Ca2+ dependence of these prejunctional effects. Segments of canine saphenous veins were mounted for isometric tension recording in organ chambers filled with Krebs-Ringer or Tyrode solution. Altering the Ca2+ concentration of the solution did not affect the inhibitory response to acetylcholine during nerve stimulation; the prejunctional potency of adenosine was inversely related to the Ca2+ concentration of the bath content. the ionophore A23187 caused contractions which were inhibited by phentolamine, verapamil, and adenosine but were augmented by acetylcholine. Helical strips of dog saphenous veins were incubated in [3H]norepinephrine and mounted for superfusion and determination of [3H]norepinephrine in the superfusate. A23187 increased the overflow of [3H]norepinephrine. Acetylcholine augmented this efflux; by contrast adenosine decreased the release induced by the ionophore. The results demonstrate that the prejunctional effect of acetylcholine was not due to direct interference with the availability of Ca2+ for the electro-secretory process in adrenergic nerve terminals and suggest that adenosine interferes either with the coupling role of the activator ion or its extrusion from the neuroplasm.


Asunto(s)
Acetilcolina/fisiología , Adenosina/fisiología , Calcio/fisiología , Sistema Nervioso Simpático/fisiología , Transmisión Sináptica , Animales , Perros , Femenino , Técnicas In Vitro , Masculino , Contracción Muscular , Músculo Liso Vascular/fisiología , Norepinefrina/metabolismo , Vena Safena/inervación
17.
Blood Vessels ; 18(6): 281-95, 1981.
Artículo en Inglés | MEDLINE | ID: mdl-7326437

RESUMEN

Experiments were performed to investigate the effect of moderate cooling on adrenergic neuroeffector interaction in canine cutaneous veins. Helical strips of dog's saphenous vein, untreated or first incubated with 3H-norepinephrine were mounted for superfusion and isometric tension recording; the overflow of endogenous catecholamines or 3H-norepinephrine and its metabolites, respectively, were measured in the superfusate. In other experiments the monoamine oxidase activity or the catechol-O-methyltransferase (COMT) activity of the saphenous vein wall was determined. Moderate cooling (from 37 to 24 degree C) decreased the evoked release of endogenous norepinephrine during electrical stimulation of the adrenergic nerve endings in the blood vessel wall. Moderate cooling depressed the overflow of 3H-norepinephrine and its metabolites in unstimulated preparations, during electrical stimulation during superfusion with high K+ solution and during exposure to tyramine. Moderate cooling reduced the activity of monoamine oxidase significantly more than that of COMT. The relative alterations in overflow of norepinephrine and its metabolites caused by a same degree of cooling in basal conditions and during the different forms of increased overflow of adrenergic transmitter suggest that lowering the temperature inhibits the exocytotic process, but at the same time slows down the diffusion of norepinephrine from the junctional cleft to the extracellular space to the extent that during sympathetic nerve stimulation at 24 degree C the effective junctional concentration of the transmitter may be comparable to that obtained at 37 degree C. The inhibitory effect of moderate cooling on the extraneuronal metabolism of norepinephrine appears to affect little the effective junctional concentration of the adrenergic transmitter.


Asunto(s)
Fibras Adrenérgicas/fisiología , Unión Neuroefectora/fisiología , Vena Safena/fisiología , Temperatura , Animales , Catecol O-Metiltransferasa/metabolismo , Perros , Estimulación Eléctrica , Ácidos Mandélicos/metabolismo , Metoxihidroxifenilglicol/metabolismo , Monoaminooxidasa/metabolismo , Contracción Muscular/efectos de los fármacos , Norepinefrina/metabolismo , Normetanefrina/metabolismo , Potasio/farmacología , Vena Safena/inervación , Piel/irrigación sanguínea , Tiramina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA